---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-065926"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2025-07-07T23:59:59+00:00"
generated_at: "2026-05-18T09:21:56.586412+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Apogee: Phase 2 APG777 hits all endpoints; EASI-75 66.9% (42.5% placebo-adjusted), safety favorable

## Summary
- APEX Part A met primary endpoint: 71% mean EASI reduction vs 33.8% placebo (p<0.001).
- EASI-75 achieved by 66.9% of APG777 patients vs 24.6% placebo (p<0.001); highest of any biologic in global study.
- Rapid itch relief: 50.7% reduction in Itch NRS at Week 1 (p<0.01). Safety well-tolerated, no injection site reactions.
- Exposure-response: top quartiles had 83-89% EASI-75; Part B testing higher dose, readout mid-2026.
- 52-week maintenance data expected 1H 2026; APG279 Phase 1b vs DUPIXENT dosed, readout 2H 2026.

## SEC filing metadata
- accession: 0001104659-25-065926
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2025-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465925065926/0001104659-25-065926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465925065926/tm2519512d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-065926
- JSON: https://secwatch.observer/filing/0001104659-25-065926.json
- Plain text: https://secwatch.observer/filing/0001104659-25-065926.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.